Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation)

Next Previous
Trial Profile

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Visugromab (Primary)
  • Indications Bladder cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms GDFATHER; GDFATHER-2; GDFather-2
  • Sponsors CatalYm

Most Recent Events

  • 20 Oct 2025 According to a CatalYm media release, data from the trial were presented at the European Society of Medical Oncology (ESMO) Congress 2025.
  • 20 Oct 2025 Results presented in the CatalYm Media Release
  • 22 Sep 2025 According to a CatalYm media release, today announced upcoming oral presentations highlighting data from this trial to be presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17th-21st, 2025, in Berlin, Germany.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top